316 related articles for article (PubMed ID: 29966936)
1. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
5. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
7. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences.
Buttigliero C; Allis S; Tucci M; Zichi C; Leone G; Di Stefano RF; Ruo Redda MG; Ricardi U; Scagliotti GV; Di Maio M; Filippi AR
Cancer Treat Rev; 2018 Sep; 69():215-223. PubMed ID: 30096699
[TBL] [Abstract][Full Text] [Related]
8. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
[TBL] [Abstract][Full Text] [Related]
9. Targeting immune checkpoints in malignant glioma.
Zhang X; Zhu S; Li T; Liu YJ; Chen W; Chen J
Oncotarget; 2017 Jan; 8(4):7157-7174. PubMed ID: 27756892
[TBL] [Abstract][Full Text] [Related]
10. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
11. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.
Caccese M; Indraccolo S; Zagonel V; Lombardi G
Crit Rev Oncol Hematol; 2019 Mar; 135():128-134. PubMed ID: 30819441
[TBL] [Abstract][Full Text] [Related]
13. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D; Martuza RL; Rabkin SD
Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Economopoulou P; Kotsantis I; Psyrri A
Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
[TBL] [Abstract][Full Text] [Related]
15. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
17. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Xue S; Hu M; Iyer V; Yu J
J Hematol Oncol; 2017 Apr; 10(1):81. PubMed ID: 28388955
[TBL] [Abstract][Full Text] [Related]
18. Update on immune checkpoint inhibitors in lung cancer.
Creelan BC
Cancer Control; 2014 Jan; 21(1):80-9. PubMed ID: 24357746
[TBL] [Abstract][Full Text] [Related]
19. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
20. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
Di Nunno V; De Luca E; Buttigliero C; Tucci M; Vignani F; Gatto L; Zichi C; Ardizzoni A; Di Maio M; Massari F
Crit Rev Oncol Hematol; 2018 Sep; 129():124-132. PubMed ID: 30097230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
